GW & Wade’s AstraZeneca AZN Stock Holding History

GW & Wade’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-2,737	Closed	-$362K	–	381
2022 Q2	$362K	Buy	2,737 +950	+53%	+$125K	0.02%	284
2022 Q1	$237K	Buy	+1,787	New	+$214K	0.01%	356

Other funds holding AZN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $63.1B AUM 23.07% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CIBC Private Wealth Group Atlanta, Georgia $59.2B AUM 20.62% 1-Year Est. Return

GW & Wade's AZN Position: Q3 2022 in Review

GW & Wade sold out of AstraZeneca (AZN) in Q3 2022, closing a stake of 2,737 shares — an estimated $362K sold.

GW & Wade first reported a position in AZN in Q1 2022 and held it in 2 quarters. The position peaked at $362K in Q2 2022. 965 funds tracked by Wall St. Rank hold AZN as of Q3 2022.

GW & Wade reported no remaining AstraZeneca position as of Q3 2022 after selling out during the quarter.
GW & Wade sold 2,737 AstraZeneca shares in Q3 2022, an estimated $362K.
GW & Wade first reported a position in AstraZeneca in Q1 2022 and held it in 2 quarters.
GW & Wade's AstraZeneca position peaked at $362K in Q2 2022.
965 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2022.

Based on GW & Wade's 13F filing for Q3 2022, filed 10 Nov 2022.